The New England journal of medicine

• Latest
• Best
• Search…

• N. Engl. J. Med. · Dec 2022

  U.S. Health Insurance Coverage and Financing.

  no abstract available

  read more… or not…

• N. Engl. J. Med. · Dec 2022

  Letter

  Resurgence of Cholera in Haiti amidst Humanitarian Crises.

  no abstract available

  read on… or not…

• N. Engl. J. Med. · Dec 2022

  Revaluing Primary Care - Going Beyond RVU Increases.

  no abstract available

  expand abstract… or not…

• N. Engl. J. Med. · Dec 2022

  Editorial Comment

  Biologics in Eosinophilic Esophagitis - Ready for Prime Time?

  no abstract available

  keep reading… or not…

• N. Engl. J. Med. · Dec 2022

  Dupilumab in Adults and Adolescents with Eosinophilic Esophagitis.

  Dupilumab, a fully human monoclonal antibody, blocks interleukin-4 and interleukin-13 signaling, which have key roles in eosinophilic esophagitis. ⋯ Among patients with eosinophilic esophagitis, subcutaneous dupilumab administered weekly improved histologic outcomes and alleviated symptoms of the disease. (Funded by Sanofi and Regeneron Pharmaceuticals; ClinicalTrials.gov number, NCT03633617.).

  explore more… or not…